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Abstract
Background: Non-small cell lung cancer (NSCLC) presents as a progressive disease spanning precancerous, preinvasive,
locally invasive, and metastatic lesions. Identification of biological pathways reflective of these progressive stages, and
aberrantly expressed genes associated with these pathways, would conceivably enhance therapeutic approaches to this
devastating disease.
Methodology/Principal Findings: Through the construction and analysis of SAGE libraries, we have determined
transcriptome profiles for preinvasive carcinoma-in-situ (CIS) and invasive squamous cell carcinoma (SCC) of the lung,
and compared these with expression profiles generated from both bronchial epithelium, and precancerous metaplastic and
dysplastic lesions using Ingenuity Pathway Analysis. Expression of genes associated with epidermal development, and loss of
expression of genes associated with mucociliary biology, are predominant features of CIS, largely shared with precancerous
lesions. Additionally, expression of genes associated with xenobiotic metabolism/detoxification is a notable feature of CIS,
and is largely maintained in invasive cancer. Genes related to tissue fibrosis and acute phase immune response are
characteristic of the invasive SCC phenotype. Moreover, the data presented here suggests that tissue remodeling/fibrosis is
initiated at the early stages of CIS. Additionally, this study indicates that alteration in copy-number status represents a
plausible mechanism for differential gene expression in CIS and invasive SCC.
Conclusions/Significance: This study is the first report of large-scale expression profiling of CIS of the lung. Unbiased
expression profiling of these preinvasive and invasive lesions provides a platform for further investigations into the
molecular genetic events relevant to early stages of squamous NSCLC development. Additionally, up-regulated genes
detected at extreme differences between CIS and invasive cancer may have potential to serve as biomarkers for early
detection.
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Introduction
Lung cancer is estimated to inflict the highest cancer mortality
rate in the United States in 2009 [1]. Molecular-targeted therapies
directed towards signal transduction pathways active in cellular
proliferation, differentiation, apoptosis, and angiogenesis, have
been used in the treatment of non-small cell lung cancer (NSCLC),
but with varied and often disappointing results [2,3,4,5,6]. As the
simultaneous targeting of multiple signaling pathways has shown
improvements in clinical response [6], further knowledge of
biological pathways involved in lung cancer development, along
with identification of aberrantly expressed genes within these
pathways, would be expected to facilitate development of novel
therapeutic intervention [7,8].
Carcinoma-in-situ (CIS) of the lung, are preinvasive lesions of
squamous NSCLC, frequently associated with histological, cytolog-
ical, and genetic aberrations, and progression to invasive cancer
typically ensues [9,10,11,12]. As these minute lesions are optimally
visible in the central airways by fluorescent bronchoscopy or LIFE
(lung-imaging fluorescent endoscopy) [13,14], experimental and
clinical studies are rare (Figure 1). Although many expression
profiling studies have been reported for advanced stage lung tumors
[15,16], early stage (CIS and locally invasive) lesions remain largely
unexplored. Molecular genetic analysis of preinvasive lesions, free
from backgroundnoiseassociatedwithcommonlystudied advanced
tumors, is essential to the identification of key genes and
corresponding molecular pathways underlying early events in
neoplastic transformation and cancer development. An understand-
ing of these early aberrations is essential for prompt therapeutic
intervention of this devastating disease.
Large-scale gene expression studies frequently employ micro-
array technologies. Recent studies emphasize the value of tailor-
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gene expression, to more accurately reflect the transcriptome of
the tissue of interest; specifically applied to the study of NSCLC
[17]. SAGE (serial analysis of gene expression) offers a sequence-
based, non-biased approach to comprehensive transcriptome
analysis, with no prior knowledge of expression required [18].
Moreover, information gained from SAGE analysis potentially
contributes to design of more appropriate microarrays for focused
research and diagnostic purposes.
In a previous study, we described the transcriptomes of smoke-
damaged bronchial epithelium and lung parenchyma by way of
SAGE [19]. Here we extend our analysis to the unexplored
preinvasive stage in lung cancer development, and present the first
report of large-scale expression profiling of carcinoma-in-situ of
the lung. Additionally, we describe transcriptomes for invasive
squamous cell carcinoma (SCC), and precancerous metaplastic
and dysplastic (PC) lesions, derived from the construction and
analysis of multiple SAGE libraries, culminating in greater than 22
megabases of sequence information. Through the utilization of
Ingenuity Pathway Analysis, we have identified genes associated with
epidermal development and xenobiotic metabolism/detoxification
as components of CIS lesions, and genes associated with immune
response and tissue remodeling/fibrosis as components of invasive
SCC. Additionally, we found genes associated with mucociliary
differentiation to be down-regulated in both CIS and PC lesions.
We discuss the potential relevance of these transcriptional
aberrations to the early stages of lung cancer development, and
present a view of the CIS transcriptome previously unknown.
Materials and Methods
Ethics statement
This study was approved by the University of British Columbia-
British Columbia Cancer Agency Research Ethics Board (UBC-
BCCA REB). Written consent was obtained from all subjects.
Specimens
Bronchial epithelial (BE) brushing specimens were previously
described [19]. Biopsy specimens included precancerous (PC)
lesions (metaplasia, dysplasia), carcinoma-in-situ (CIS) lesions, and
invasive squamous cell carcinoma (SCC) tumor tissue. PC and CIS
specimens were obtained by autofluorescent bronchoscopy
(Figure 1). All biopsies (except for those used in constructing
libraries CIS-3, SCC-5, and SCC-6) were collected in RNAlaterH
[Applied Biosystems (Ambion Inc., Canada)] and stored at
285uC. The biopsy used in construction of library CIS-3 was
embedded in OCT media, and stored at 285uC. For construction
of libraries SCC-5 and SCC-6, RNA was isolated from tumor
tissue from eight individuals by guanidium isothiocyanate and
phenol/chloroform extraction. All subjects contributing to this
study were either former or current smokers (Table 1).
SAGE library construction and sequence processing
With the exception of construction of libraries SCC-5 and SCC-
6, each specimen (biopsy or bronchial brushing as previously
described [19]) was retrieved from RNAlaterH (or OCT for library
CIS-3), and homogenized in lysis/binding solution. For libraries
SCC-5 and SCC-6, RNA was pooled from four specimens in equal
amount, and ,19 mg of total RNA were immersed in lysis/binding
solution and used for construction of each library. The resultant
lysates were used directly for SAGE library construction according
to the MicroSAGE protocol, using Nla III as the anchoring enzyme
and Bsm FI as the tagging enzyme (www.ncbi.gov/SAGE). This
approach was shown to yield highly reproducible SAGE libraries
[19]. On average, 10
5 SAGE tags, excluding linker and duplicate
ditags, were sequenced per library; all raw SAGE data has been
deposited with GEO (Table 1). For normalization, tag counts were
scaled to 10
6 tags for each library, i.e. as tags per million (TPM).
Cluster analysis
To evaluate the degree of similarity among the lung SAGE
libraries generated in this study (two PC libraries, five CIS libraries,
and six invasive SCC libraries) and those generated in a previous
study (14 BE libraries, and two lung parenchyma libraries), cluster
analysis was used. For this analysis, the 300 most abundant tags
were retained from each library, yielding a merged list of 1128
unique tags. The data were then log10 transformed and clustered
using Genesis, using an average-linkage algorithm and a Euclidean
distance metric [20]. For tags with counts of zero, the data was not
transformed, and was retained as zero.
Differential expression analysis
Unless stated otherwise, differential gene expression was defined
by a minimal three-fold difference (rounded to one decimal place)
in average normalized tag counts (TPM) between any two datasets
being compared. In addition, a minimal average normalized tag
count of 40 TPM was required in the over-expressing dataset.
Tag-to-gene mapping was according to the SAGE Genie database,
September 17, 2009 version [21] (cgap.nci.nih.gov/SAGE). As the
newest release of SAGE Genie does not automatically align to
mitochondrial transcripts, we utilized a manual mapping approach
to identify these transcripts.
Figure 1. Detection of carcinoma-in-situ bronchial lesions. Bronchoscopy using A. white light for detection of CIS lesions (indicated by arrow),
or B. LIFE (lung-imagine fluorescent endoscopy) for detection of CIS lesions (indicated by arrow). C. Histological section identifying a CIS lesion within
the bronchial epithelium, typified by extensive squamous stratification.
doi:10.1371/journal.pone.0009162.g001
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Datasets of differentially expressed genes were analyzed primarily
through the use of Ingenuity Pathway Analysis (IPA), version 8.0
(IngenuityH Systems, www.ingenuity.com). Functional analysis of entire
datasets identified the biological functions and/or diseases that were
most significant to the dataset. Genes from the dataset that were
associated with biological functions and/or diseases in the Ingenuity
Pathways Knowledge Base were considered for the analysis (IPA
eligible mapped IDs). Canonical pathway analysis of entire datasets
identified the pathways from the IPA library of canonical pathways
that were most significant to the dataset, based upon genes within
the dataset that were associated with a canonical pathway in the
Ingenuity Pathways Knowledge Base. Toxicity list analysis of entire
datasets identified the Tox lists from the IPA library of Tox Lists that
were most significant to the dataset. Genes from the dataset that
were associated with a List were considered for the analysis. For
each of these analyses, the significance of the association between
the genes in the dataset and the assigned biological function and/or
disease/canonical pathway/toxicity list, was measured by Fischer’s
exact test to calculate a p-value to determine the probability that the
association was explained by chance alone.
My Pathways is a graphical representation of the biological
relationships between gene products, which are supported by at
least one reference from the literature, from a textbook, or from
canonical information stored in the Ingenuity Pathways Knowl-
edge Base. Genes are displayed using various shapes that represent
the functional class of the gene product as indicated in the legend
within the specific figures.
RNA isolation from clinical specimens
For quantitative RT-PCR analysis, RNA from matched tumor
and normal lung parenchyma were collected from resected tissues.
Table 1. Summary of patient demographics and library descriptions.
Library
1 Gender Age Smoking status Pathology Useful tags sequenced GEO Series Accession
BE-3
2 M 68 former NA 152,086 GSE5473
BE-4A&4B M 69 former NA 222,395 GSE3707
BE-5
2 M 70 former NA 158,288 GSE5473
BE-6 M 67 former NA 91,571 GSE3707
BE-7 M 56 current NA 81,309 GSE3707
BE8B M 72 former NA 81,799 GSE5473
BE-9
2 M 68 former NA 162,903 GSE5473
BE-10 M 65 former NA 86,725 GSE3707
BE-11A F 56 former NA 89,622 GSE3707
BE-12 F 63 current NA 88,186 GSE3707
BE-13
2 F 63 current NA 93,345 GSE5473
BE-14 F 63 former NA 155,462 GSE3707
BE-15 M 72 former NA 143,129 GSE3707
BE-16 F 71 former NA 131,285 GSE3707
BE total = 1,738,105
CIS-1 M 61 former in-situ 163,460 GSE7898
3
CIS-2 M 68 former in-situ 160,466 GSE7898
CIS-3 M 69 current in-situ 201,617 GSE7898
CIS-4 M 70 former in-situ 174,246 GSE7898
CIS-5 M 72 former in-situ 211,034 GSE7898
CIS total = 910,823 GSE7898
SCC-1 M 78 current invasive 150,712 GSE7898
SCC-2 M 62 former invasive 152,220 GSE7898
SCC-3 M 70 current invasive 208,451 GSE7898
SCC-4 M 68 former invasive 176,874 GSE7898
SCC-5 1M/3F 54, 64, 75, 84 former/current invasive 152,786 GSE7898
SCC-6 4M 65, 69, 74, 77 former/current invasive 150,233 GSE7898
SCC total = 991,276 GSE7898
Met M 51 current metaplasia 202,340 GSE7898
Dys M 71 former dysplasia 155,185 GSE7898
Precancer total = 357,525
BE, bronchial epithelial; CIS, carcinoma in-situ; SCC, invasive squamous cell carcinoma; Met, metaplasia; Dys, dysplasia.
1With the exception of SCC-5 and SCC-6, all libraries were constructed from single individuals; the former of which were constructed from two pools of four individuals
each.
2With deeper sequencing of previously reported libraries generated in previous studies [19,37].
3All libraries constructed in this study were submitted to GEO as a single series.
doi:10.1371/journal.pone.0009162.t001
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last in a series stained with H&E for inspection by a lung
pathologist. After confirming diagnosis and assessing tumor
heterogeneity with pathology review, we captured those portions
of the tumor having a minimum of 70% cancer cells. RNA was
extracted from both microdissected tumor tissue and from
associated normal tissue with the RNeasy kit (Qiagen, Mississauga,
ON, Canada). In total, RNA from nine paired tumor and normal
parenchyma samples was used for RT-PCR analysis. In addition,
RNA was extracted as previously described [19], from six
bronchial brushings representing three current and three former
smokers, for quantitative RT-PCR analysis.
RT-PCR analysis
For quantitative RT-PCR (qPCR), approximately 1 mgt o t a lR N A
was converted into cDNA using the High-Capacity cDNA Archive
kit (cat# 4322171, Applied Biosystems), and gene-specific quantita-
tive PCR was performed using TaqMan Universal PCR Master Mix
and TaqMan primers (cat# 4326708; Applied Biosystems), accord-
ing to manufacturer’s recommendation. Beta-actin was used as an
endogenous control (primer product code 4352935E). Primer
product codes for test genes were as follows: ECE2 (Hs00981189_
g1), MAGEA9 (Hs00245619_s1), MAGEA11 (Hs00377815_m1),
CLDN1 (Hs00221623_m1), CKS1B (Hs01029137_g1), POSTN
(Hs00170815_m1), ARTN (Hs00754699_s1), SFRP2 (Hs00293258_
m1), UBE2S (Hs00819350_m1), C19orf48 (Hs00364147_m1),
FBXO27 (Hs00381091_m1), MCM2 (Hs00170472_m1), NTS
(Hs00175048_m1), SLC6A8 (Hs00373917_g1), and SLC2A1
(Hs00197884_m1, Hs00892681_m1). The reactions were run on
an iCycler iQ Real-Time PCR Detection System (Bio-Rad
Laboratories (Canada) Ltd., Mississauga, ON, Canada). Differential
expression was determined using the delta-delta CT method. For the
tumor/normal parenchyma pairs, fold changes were calculated for
each pair. When comparing the tumors to the brushings,foldchanges
were calculated comparing each tumor to the average expression of
thesixBEsamples.Theaveragetumorovernormalparenchymafold
change and the average tumor over BE fold change are reported for
each gene.
Gene dosage determination
Carcinoma-in-situ specimens used for copy-number profiling
were collected in 10% buffered formalin. Microdissection was
performed on paraffin sections to obtain cancer cells. Typically
greater than 20 serial sections were necessary to yield sufficient
material. DNA was isolated from collected cells by proteinase K
phenol/chloroform extraction as previously described [22]. Whole
genome tiling path array CGH analysis was performed using
SMRT array version 2 as previously described [23,24]. This
platform is suitable for profiling formalin fixed paraffin embedded
material [22,23,25,26,27,28,29,30]. Genome segmentation and
copy number status was performed using aCGH-Smooth on array
image data and visualized using SIGMA software [31,32,33,34].
Loss array elements were assigned a value of 21, retained
elements a value of 0, and gained elements a value of 1. Twenty
CIS specimens were profiled in total, and a threshold for gene-
specific copy number gain/loss was set at 20%. The 20%
threshold was imposed in an effort to reduce the detection of
spurious or random events due to background genomic instability
inherent to the samples, and thereby selecting for those events
which occur with some degree of regularity.
Public microarray data comparisons
Microarray expression data for 53 primary squamous tumors
was retrieved from the Lung Cancer Dataset at NCBI, GEO
accession number GSE3141 [35]. Microarray expression data for
67 bronchial brushings retrieved from a mixed population of
current and former smokers, was profiled internally. All micro-
array data was RMA normalized [36].
Results and Discussion
SAGE offers an unbiased and comprehensive approach to
expression profiling, limited only by the depth of sequencing
chosen by the researcher, and offers an unprecedented opportu-
nity for transcript discovery. This is in sharp contrast to
microarray analysis, where expression profile and scope of
analysis is predetermined by target design typically employing a
limited number of the most commonly characterized genes [17].
In a previous study, we described the transcriptomes of smoke-
damaged bronchial epithelium and lung parenchyma by way of
SAGE [19]. Here we extend our analysis to the largely unexplored
area of early-stage lung cancer development, and present the first
report of large-scale gene expression profiling of carcinoma-in-situ
(CIS) of the lung. An understanding of the molecular genetics
governing the preinvasive stages is critical to facilitate early
detection and immediate therapeutic intervention before progres-
sion to invasive cancer ensues. In the current study, we present a
comparative analyses, with emphasis on genes over-expressed in
CIS and invasive cancer transcriptomes, relative to non-cancerous
transcriptomes of the lung including bronchial epithelium
(BE), and precancerous lesions (PC: squamous metaplasia and
dysplasia).
Twenty-seven lung SAGE libraries comprised of 3,997,729 total
sequence tags (,40 megabases of high quality DNA sequence)
were analyzed in this study. Normal lung is represented by 14
bronchial epithelial libraries (BE-1 through BE-14) [19,37].
Precancer stage is represented by two libraries derived from
squamous metaplasia (Met) and squamous dysplasia (Dys).
Squamous cell carcinoma of the lung is represented by five
carcinoma in-situ libraries (CIS-1 through CIS-5), and six invasive
carcinoma libraries (SCC-1 through SCC-6) (detailed in Table 1
and Table 2). (It is noted that specimens comprising the BE, PC,
CIS, and SCC datasets were from a mixed population of current
and former smokers.) This data has identified greater than 129,000
unique sequence tags/potential transcripts in CIS lesions, and
nearly 140,000 unique sequence tags/potential transcripts in
invasive squamous NSCLC.
Table 2. Summary of SAGE libraries generated and tags
sequenced.
BE
3 Precancer CIS SCC Total
Libraries 14 2 5 6 27
Tags Sequenced 1,738,105 357,525 910,823 991,276 3,997,729
Unique tags (UT)
1 177,713 70,043 129,683 139,843 304,568
UTs excl. singleton
2 76,471 24,661 49,054 52,017 150,331
BE, bronchial epithelial; Precancer (squamous metaplasia, squamous dysplasia);
CIS, carcinoma-in-situ; SCC, invasive squamous cell carcinoma.
1Unique tags are defined by the 10 nucleotide long sequence, and represent
the maximum number of unique transcripts within the respective SAGE
dataset.
2Exclusion of singletons; singleton is defined as sequence tags having a raw tag
count of one within an individual dataset (comprised of multiple libraries as
indicated).
3BE libraries were generated in previous studies [19,37].
doi:10.1371/journal.pone.0009162.t002
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and SCC SAGE datasets
Cluster analysis. Cluster analysis yielded anticipated
grouping of SAGE libraries, attesting to sample quality. For
this analysis, the 300 most abundant tags were retained from each
library, yielding a merged list of 1128 unique tags. Average
linkage clustering analysis based on the 1128 most abundant
SAGE tags, reveals that all cancer libraries (both CIS and
invasive SCC) cluster together, and separately from the BE
libraries (Figure 2A). We note some clustering of the invasive
SCC libraries (four out of six). Similar clustering is observed when
using the top 500 or top 1000 unique tags per library (data not
shown).
Ingenuity pathway analysis. To characterize and compare
the bronchial epithelial and cancer transcriptomes, we computated
average normalized tag counts for BE (14 libraries), CIS (5
libraries), and invasive SCC (6 libraries) datasets, and subsequently
selected the most abundant 300 unique tags from each dataset for
analysis (Table S1). Tags mapping to mitochondrial-encoded
genes and ribosomal protein genes, were found at similar
frequencies within the top 300 most abundant tags, across all
three datasets of BE, CIS, and SCC, at ,8% and ,18%,
respectively. We used the core analysis component of Ingenuity
Pathway Analysis (IPA) to categorize these genes according to
biological functions. Only those molecules having at least one
functional annotation in the IPA Knowledge Base qualify for
analysis, and included 220 (BE), 231 (CIS), and 233 (SCC) IPA
eligible genes. These analyses reveal that genes within the category
of Hair and Skin Development and Function are highly expressed in the
CIS transcriptome relative to both BE and SCC, and genes within
the categories of Hematological System Development and Function and
Immune Cell Trafficking are highly expressed in the SCC
Figure 2. Analysis of the top 300 most abundant tags from the BE, CIS, and invasive cancer datasets. A. Cluster analysis of lung SAGE
libraries. All SAGE libraries from this study, including five carcinoma in-situ libraries (CIS-1 through CIS-5), six invasive squamous cell carcinoma
libraries (SCC-1 through SCC-6), one squamous metaplasia library (Met), and one squamous dysplasia library (Dys), as well as 14 bronchial epithelial
libraries (BE-1 through BE-14), and two normal lung parenchyma SAGE libraries (LP-1, LP-2; accession GSE3708) generated in a previous study [19,37],
were analyzed by cluster analysis using an average-linkage algorithm. The top 300 most abundant tags were retained from each library, and analysis
was based on 1128 unique tags in total. In the dendrogram, branch length represents distance. B–D. IPA functional analysis of the most abundant
genes in the BE, CIS, and invasive cancer datasets. Tag-to-gene mappings for the top 300 most abundant tags from the BE, CIS, and SCC datasets,
were used for IPA core analysis, consisting of 220, 231, and 233 IPA eligible mapped IDs, respectively. The three sets of data were displayed together
using IPA core comparisons, and the five most significant functions within Physiological System Development and Function are shown for each of the
three datasets. The data in B is sorted according to highest significance in BE, the data in C is sorted according to highest significance in CIS, and the
data in D is sorted according to highest significance in invasive SCC. The orange line indicates the threshold limit of significance, preset at a p-value of
0.05. For a complete listing of the tags/mapped IDs used for this analysis see Table S1.
doi:10.1371/journal.pone.0009162.g002
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expression of genes associated with epidermal development is
identified here as a characteristic feature of the CIS transcriptome,
and high expression of genes associated with cellular movement as
a characteristic feature of the SCC transcriptome. See Figure 2B–
D for a summary of these analyses.
A notable feature of both the CIS and SCC datasets is the
abundance of tags mapping to the constant region of immuno-
globulin heavy chains. In fact, the SAGE tag for IGHG1 is the
most abundant tag in both the CIS and the invasive cancer
datasets (Table S1). Although it is possible that expression of these
immunoglobulin chains originates from infiltrating lymphoid tissue
and surrounding stroma, previous studies have demonstrated
expression of heavy chain constant and variable regions of
immunoglobulins in breast cancer epithelial cells [38,39,40], and
expression of IgG heavy and light chains in various epithelial
cancer cells including lung SCC [41]. These immunoglobulin
chains may represent cancer cell autoantibodies, and stimulate
growth in an autocrine/paracrine fashion [40]. Intriguingly, the
abundance of tags mapping to immunoglobulin heavy chain
transcripts in CIS preinvasive lesions of the lung, in contrast to the
relatively low detection in both BE and precancerous metaplastic
and dysplastic lesions (detailed in subsequent tables), suggests that
up-regulation of these transcripts may have relevance to initiation
of NSCLC.
Gene expression changes common to carcinoma-in-situ
and precancerous lesions
Transition from a healthy bronchial epithelium to invasive
cancer is thought to proceed via progression of histological and
genetic abnormalities: BE to PC to CIS to SCC, where PC
represents precancerous lesions (squamous metaplasia and dyspla-
sia). Squamous metaplasia is a transient component of normal
wound healing of the bronchial epithelium, and typically resolves
to a re-differentiated epithelium composed of pseudostratified
ciliated and secretory cells, restoring bronchial function [42]. (Use
of the term PC here does not imply an obligatory progression to
cancer, but rather refers to lesions/abnormalities that despite
infrequent progression to cancer, are considered as precursors to
cancer.) Conversely, CIS lesions demonstrate a low regression
frequency with a high incidence of progression to invasive cancer
[43,44] and are characterized by a more extensive stratification of
squamous cell types compared to PC [9,11,12]. By identifying
gene expression changes common to both PC and CIS relative to
BE, we focus on those genetic events which occur early and persist
through to CIS. In accordance with our selection criteria (minimal
three-fold difference in average normalized tag abundance;
minimal average normalized tag abundance of 40 TPM in the
over-expressing dataset), 868 SAGE tags were found to be
similarly differentially expressed in PC and CIS relative to BE,
consisting of 190 up-regulated tags, and 678 down-regulated tags
(Figure 3A).
Up-regulated expression changes. Approximately 35% of
the tags up-regulated in CIS relative to BE (190 out of 529 tags)
were found to be commonly up-regulated in PC lesions, and
approximately 25% of tags up-regulated in PC lesions relative to
BE (190 out of 754 tags) were found to be similarly up-regulated in
CIS (Figure 3A). See Table S2 for a description of these tags up-
regulated in both PC and CIS. IPA functional analysis (based on
143 eligible mapped IDs) indicates that roughly 35% of these
commonly up-regulated genes are associated with epidermal
development and associated disorders, as described in Table 3.
In addition to those genes described in Table 3, a review of the
literature identified other genes within the PC/CIS up-regulated
dataset to be associated with epidermal development, including
SBSN, CNFN, CRCT1, additional members of the small proline-
rich family of proteins (SPRR2E and SPRR3), and additional
members of the S100A family of calcium-binding proteins. Many
of these genes are encoded either within the epidermal
differentiation complex (EDC) locus on 1q21 [45,46] or within a
conserved locus on 19q13 [47], and specify components of the
cornified cell envelope, a structure that provides barrier protection
to epidermis and internal epithelium in response to insult or injury
[48,49].
IPA pathway graphical representation of the genes commonly
up-regulated in CIS and PC relative to BE, is presented in
Figure 4. Considering the molecular interactions identified by
IPA, functional associations among desmosomal cadherins and
catenins are prominent within the PC/CIS up-regulated
dataset. Desmosomes are intercellular adhesion junctions that
provide mechanical integrity to the epithelium, and studies
indicate that desmosomal cadherins modulate keratinocyte
differentiation and epidermal morphogenesis [50]. This analysis
also suggests that a signaling cascade mediated by members of
the 14-3-3 family of proteins, may be active here. 14-3-3 sigma
(SFN) mediates keratinocyte differentiation and stratification of
epidermis [51]. The pathway diagram also suggests that specific
Figure 3. Venn diagrams of differentially expressed genes
discussed in this manuscript. Criteria for differential gene expres-
sion was defined as a minimal three-fold difference in normalized mean
tag counts, and with a minimal mean tag abundance of 40 TPM in the
over-expressing datasets. Up-arrows indicate up-regulated gene
expression changes; down-arrows indicate down-regulated gene
expression changes; numerical values refer to the number of
differentially expressed tags. Areas of interception reflect gene
expression changes in common between the two datasets. A.
Expression changes in carcinoma-in-situ and precancerous lesions
relative to BE. B. Expression changes in the cancer datasets relative
to both bronchial epithelium and precancerous datasets. BE: bronchial
epithelial; PC: precancer; CIS: carcinoma-in-situ; SCC: invasive squamous
cell carcinoma.
doi:10.1371/journal.pone.0009162.g003
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by the AP-1 transcription factor FOSL2, which may have an
additional role in extracellular matrix remodeling. Indeed,
FOSL2 has been identified as a mediator of pulmonary fibrosis
[52]. A consideration of genes associated with the transcription
factor HIF1A in the PC/CIS lesions, is suggestive of a
remodeling/profibrotic response to hypoxic growth conditions
[53,54,55]. Indeed, a functional link between hypoxia and
fibrosis is documented in the literature [56,57,58]. Expression of
other genes identified here, such as NCF1 (the regulatory
subunit of NADPH oxidase), and the heme catabolic enzyme
HMOX1, is also indicative of an oxygen-related stress response
and tissue remodeling/fibrosis [59,60,61,62]. It is noted that
additional IPA analysis identified Hepatic Fibrosis/Hepatic Stellate
Cell Activation and 14-3-3-mediated Signaling as significant catego-
ries within Canonical Pathways,a n di d e n t i f i e dHepatic Fibrosis as
the most significant category within Toxicity Lists (data not
shown).
Additional analysis by Gene Ontology using the GATHER
annotation tool [63], similarly identified epidermal development as
a prominent component of the transcriptome of commonly up-
regulated genes in CIS and PC lesions, relative to BE (Figure
S1A, Table S3).
Down-regulated expression changes. The majority of tags
down-regulated in CIS relative to BE, were found to be commonly
down-regulated in PC lesions (678 tags out of 904 tags), and vice
versa (678 tags out of 912 tags down-regulated in PC relative to
BE) (Figure 3A). See Table S4 for a description of these tags
down-regulated in both PC and CIS. IPA functional analysis
(based on 347 eligible mapped IDs) identified Cellular Assembly and
Organization and Embryonic Development as the two most significant
functional categories (p-values 1.29E-05–4.67E-02 and 1.30E-05–
4.32E-02, respectively) for this dataset of commonly down-
regulated genes (data not shown). Within the former, seven
genes associated with biogenesis and formation of cilia were
identified. These include dynein components of the cilium
axoneme (DNAI2, DYNC2H1), FOXJ1 transcription factor and
master regulator of motile ciliogenesis [64], intraflagellar transport
proteins IFT172 and IFT88, kinesin family member KIF3A, and
BBS5, a protein family member linked to Bardet-Biedl Syndrome
and localized to ciliary basal bodies. Genes identified within the
functional category of Embryonic Development are associated with
patterning, specification of the midline axis, and formation of the
neural tube. As these developmental processes have been linked to
ciliary activity, specifically primary cilia-mediated Hedgehog
signaling [65,66], presumably this data overall reflects loss of the
ciliated cell phenotype as common to PC and CIS lesions.
We also note at a lower significance, down-regulation of genes
associated with DNA recombination and repair in CIS and PC
lesions (p-value 1.16E-04-4.42E-02). These include DNA repair
genes (CCNO and NEIL1, glycosylases associated with base-
excision repair; cyclin-dependent kinase CDK2; glycoprotein
Table 3. Genes associated with epidermal development in the CIS_PC over BE dataset by IPA functional analysis.
Function Annotation p-value Molecules
3 # Molecules
4
Category: Dermatological Diseases and Conditions
1
dermatological disorder 4.18E-17 COL1A1, COL1A2, COL3A1, COL6A1, COL7A1, DEFB103A, DEFB4, DSG1,
DSG3, DSP, FYN, GJA1, HIF1A, IGHG1, IGL@, ITGA6, JUP, KRT5, KRT14,
KRT17, KRT6A, KRT6B, LGALS1, LMNA, LTBP2, MMP1, PKP1, S100A7,
S100A8, SELL, SFN, TP63, TUBA1C, TUBA4A, TYMS
35
dermatological disorder of mammalia 2.98E-03 DSG1, DSG3, IGHG1, MMP1, SELL 5
epidermolysis bullosa 3.66E-09 COL7A1, DSP, ITGA6, KRT5, KRT14, MMP1 6
recessive epidermolysis bullosa dystrophica 8.12E-05 COL7A1, MMP1 2
burn 1.04E-04 COL1A1, COL1A2, COL3A1, COL6A1, COL7A1 5
Ehlers-Danlos syndrome 1.94E-04 COL1A1, COL1A2, COL3A1 3
skin cancer 4.53E-04 CD44, FYN, HIF1A, KLK6, MCL1, MMP2, TUBA1C, TUBA4A, TYMS 9
epidermolysis bullosa simplex 4.81E-04 KRT5, KRT14 2
skin tumor 1.62E-03 CD44, FYN, HIF1A, MCL1, MMP2, TUBA1C, TUBA4A, TYMS 8
disease of skin 2.04E-03 CAV1, DSG3, KRT14, MMP1, SELL 5
acanthosis 2.80E-03 DSG3, MMP1 2
psoriasis 3.90E-03 DEFB103A, DEFB4, IGHG1, S100A7 4
pemphigus of mice 4.23E-03 DSG1, DSG3 2
Category: Hair and skin Development and Function
2
development of epidermis 7.70E-13 COL1A1, COL7A1, DSP, EMP1, EVPL, FABP5, KRT5, KRT14, KRT17,
S100A7, SPRR1A, SPRR1B, TP63
13
development of skin 1.07E-03 COL1A1, COL3A1, SFN, TP63 4
differentiation of keratinocytes 1.12E-08 CSTA, DSP, EVPL, FABP5, IVL, SFN, SPRR1A, SPRR1B, TP63 9
cell movement of keratinocytes 4.23E-03 JUP, TP63 2
proliferation of epidermal cells 6.78E-03 JUP, KLK6, SFN, TP63 4
1IPA Diseases and Disorders.
2IPA Physiological System Development and Function.
3See Table S2 for corresponding tag abundance.
447 unique genes were identified out of 143 IPA eligible mapped IDs.
doi:10.1371/journal.pone.0009162.t003
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the G1 DNA damage checkpoint; helicase RUVBL2; TRIP13, a
regulator of double-strand break repair and meiotic checkpoint
control; antioxidant SOD1), genes associated with DNA modifi-
cation (editing enzyme APOBEC3G; antioxidant CAT), and DNA
catabolism (exoribonuclease XRN2), mediators of ATP hydrolysis
(ATPIF1, MAPK1, N4BP2, RUVBL1, RUVBL2, TGM2),
centriole duplication (AKAP9, CETN2), and folate receptor
FOLR1.
IPA pathway graphical representation of genes commonly
down-regulated in CIS and PC also highlights genes associated
with ciliogenesis including axonemal components and centrosomal
proteins, genes associated with goblet cell differentiation, and
genes associated with epithelial cell polarization and ion transport
(Figure S2). Down-regulation of these genes, as well as many
others in the BE over PC_CIS dataset also associated with
ciliogenesis but not identified as such by IPA, reflect a pronounced
loss of mucociliary differentiation in both PC and CIS lesions,
presumably accompanied by deficiency in clearance and defense
of the airways [67]. For further description of the genes identified
in Figure S2, see Text S1.
Additional analysis by Gene Ontology using the GATHER
annotation tool [63], identified processes associated with cilia
function such as gametogenesis and spermatogenesis, and
microtubule-based processes, as prominent components of the
transcriptome of commonly down-regulated genes in CIS and PC
lesions, relative to BE (Figure S1B, Table S3).
Identification of differentially expressed genes in
carcinoma-in-situ and invasive cancer transcriptomes key
to cancer development
By identifying genes differentially expressed between preinva-
sive and invasive stages of lung cancer development (CIS and
SCC, respectively), relative to both non-cancerous bronchial
epithelium and precancerous metaplasia/dysplasia lesions (BE and
PC, respectively), we propose to identify expression changes
instrumental to both initiation (CIS) and progression (SCC) of lung
cancer. In accordance with our selection criteria (minimal three-
fold difference in average normalized tag abundance; minimal
average normalized tag abundance of 40 TPM in the over-
expressing dataset), 309 SAGE tags were found to be differentially
expressed in CIS relative to BE and PC, and 280 tags were
differentially expressed in SCC relative to BE and PC, with 116
tags similarly differentially expressed (Figure 3B). It is noted that
the stringent selection criteria imposed in this study for differential
expression would preclude certain genes, although present in the
SAGE datasets and relevant to cancer development, from further
Figure 4. IPA pathway graphical representation for the CIS_PC over BE dataset of up-regulated genes. 155 genes (IPA mapped IDs) are
represented out of 190 SAGE tags up-regulated in both CIS and PC relative to BE. (See Table S2 for tag data.) Gene products are positioned according
to subcellular localization. Only direct connections (i.e., direct physical contact between two molecules) among the individual gene products are
shown for clarity of presentation; lines indicate protein-protein binding interactions, and arrows refer to ‘‘acts on’’ interactions such as proteolysis,
expression, and protein-DNA/RNA interactions. Genes associated with epidermal development (see Table 3) are highlighted.
doi:10.1371/journal.pone.0009162.g004
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the selection process, typically lends greater confidence to the
relevance of those genes identified as differentially expressed in the
cancer datasets.
Up-regulated expression changes. We identified 225
SAGE tags to be over-expressed in CIS relative to both BE and
PC (Table S5), and 232 tags to be over-expressed in invasive SCC
relative to both BE and PC (Table S6). It is noted that greater
than 35% of the over-expressed tags within the CIS dataset (85
tags) were commonly up-regulated in SCC (Figure 3B), suggesting
that significant expression changes relating to advanced cancer
have already occurred by the time a diagnosis of CIS has been
made, in accordance with irreversibility of CIS lesions.
Discrepancy between the number of up-regulated tags and the
number of IPA mapped IDs within each dataset, indicates that a
significant proportion of potentially up-regulated genes in early-
stage lung cancer remain to be identified (Figure 5A). IPA
pathway graphical representation for up-regulated tags with
mapped IDs for the two cancer datasets, is presented in
Figure 5B. A higher proportion of up-regulated gene products
are localized to the extracellular space in the SCC dataset relative
to the CIS dataset. Considering the molecular interactions
identified by IPA, functional networks involving the cell surface/
extracellular matrix adhesion protein FN1, and transcriptional/
cell cycle regulator CDKN2A, highlight the SCC dataset. Up-
regulation of FN1-interacting proteins associated with tissue
remodeling/fibrosis, and FN1-interacting proteins associated
with acute phase response, suggests a link between these
processes in SCC. A link between acute phase response and
tissue repair has been previously proposed [68]. Activation of a
CDKN2A functional network associated with cellular senescence,
may reflect a protective response of the involved organ to acute
tissue injury [69]. No outstanding molecular interactions were
apparent for the CIS up-regulated dataset. Differential expression
for a subset of the up-regulated genes in Figure 5B was validated
by real-time quantitative RT-PCR (Table S7).
Figure 5. Genes up-regulated in the CIS and invasive SCC datasets relative to BE and PC. A. Venn diagram of up-regulated SAGE tags and
corresponding IPA mapped IDs for the CIS and SCC datasets. (See Table S5 and Table S6 for description of up-regulated tags in the CIS and SCC
datasets, respectively.) B. IPA pathway graphical representation for the CIS over BE_PC dataset (80 unique IDs displayed in green; 58 shared IDs
displayed in gray), and the SCC over BE_PC dataset (112 unique IDs displayed in red; 58 shared IDs displayed in gray). Gene products are positioned
according to subcellular localization. Only direct connections (i.e., direct physical contact between two molecules) among the individual gene
products are shown for clarity of presentation; lines indicate protein-protein binding interactions, and arrows refer to ‘‘acts on’’ interactions such as
proteolysis, expression, and protein-DNA/RNA interactions. Eleven genes were detected at levels 20-fold or greater in the CIS over BE_PC dataset
relative to the invasive cancer dataset (indicated by dark green), and 10 genes were detected at levels 20-fold or greater in the SCC over BE_PC
dataset relative to the CIS dataset (indicated by dark red).
doi:10.1371/journal.pone.0009162.g005
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annotation tool [63] for genes up-regulated in CIS and SCC
relative to BE and PC (Figure S3; Table S8). This analysis
identified fatty acid biosynthesis (described by a cluster of 5 genes)
as a component of the CIS dataset. In agreement with IPA analysis
described above, gene ontology analysis identified defense
response (described by a cluster of 20 genes) as a notable
component of the invasive cancer dataset. Additionally, skeletal
development, response to wounding, anion transport, and
carbohydrate catabolism were also identified by GATHER gene
ontology analysis, as components of the invasive cancer dataset.
Epidermal development. Considering the notable
expression of genes associated with epidermal development
common to the PC and CIS datasets, we investigated whether
functionally related genes are also enriched in the cancer datasets
(CIS and SCC) relative to both BE and PC. The genes identified
from this investigation using IPA functional analysis are described
in Table 4. These data indicate that gene expression patterns
reflective of epidermal development are not restricted to
precancerous lesions, but rather also present as a component of
CIS (,15% of IPA eligible mapped IDs), and invasive cancer
(,26% of IPA eligible mapped IDs) apart from precancerous
lesions.
In addition to those genes described in Table 4, other genes
up-regulated in CIS relative to both BE and PC that are
associated with epidermal development, include KRTDAP
(encoded on19q13), KPRP, SPRR2F, SPRR2G, and LCE3D
(all encoded on 1q21). KRTDAP is associated with epidermal
morphogenesis, and is a potential regulator of keratinocyte
differentiation [70,71,72,73,74]. KPRP is an epidermal marker
expressed in stratified squamous epithelia [75], and has a
potential role in calcium-induced keratinocyte differentiation,
and expression is increased in psoriasis [76]. It is noted that genes
associated with development of the cornified cell envelope
encoded on 1q21/19q13, tend to be expressed at notably lower
levels in invasive cancer relative to CIS (see Table S2 and Table
S5).
As described in Table 4, transcriptional regulators associated
with keratinocyte differentiation over-expressed within invasive
cancer include IRF6, CDKN2A, and JUNB. IRF6 is an
interferon-induced transcription factor associated with the switch
between keratinocyte proliferation and differentiation [77]. JUNB,
a member of the AP-1 transcription factor family, is associated
with keratinocyte differentiation during wound healing and
psoriasis [78,79]. The cyclin-dependent protein kinase inhibitor/
transcription factor CDKN2A (see above), is associated with cell
cycle arrest/senescence of keratinocytes, and differentiation of
epidermis [80,81]. Although considered a tumor suppressor
protein, increased expression of CDKN2A at the invasive front
of basal cell carcinomas and colon cancer has been reported, and
the correlation of increased invasiveness with decreased prolifer-
ation, suggests that CDKN2A may play a role in cancer cell
invasion [82,83].
An association between epidermal development and squamous
cell lung cancer development is frequently studied through analysis
of the EGFR pathway [84]. Anti-EGFR therapies have been
initiated for various types of cancer, including NSCLC
[85,86,87,88]. Also, up-regulation of KGF, a member of the
fibroblast growth factor family and mediator of epidermal
differentiation, is associated with pancreatic cancer [89]. The
identification of additional genes associated with epidermal
development and up-regulated in the early stages of NSCLC,
may enhance our understanding of the role of this pathway in lung
cancer development, and broaden treatment options.
Additional IPA analysis. We utilized IPA core analysis to
identify additional functions within the CIS and invasive SCC
datasets of up-regulated genes (Figure 6). Canonical Pathways
analysis and Toxicity Lists analysis identified metabolism/
detoxification of xenobiotics as a component of the CIS dataset,
and hepatic fibrosis as a major characteristic of the invasive cancer
phenotype. Specific genes associated with these phenotypes are
listed in Table 5 and Table 6 and described below.
Metabolism/detoxification of xenobiotics. Metabolism/
detoxification of xenobiotics is a protective cellular response to
prevent damage to macromolecules upon exposure to both
exogenous and an excess of endogenous stressors [such as reactive
oxygen species (ROS)]. Most notably, glutathione metabolic
enzymes that mediate phase II detoxification of xenobiotics via
conjugation with glutathione, and members of the aldose-
reductase family of oxidoreductases, have been identified to be
up-regulated in the CIS dataset (Table 5). Most of these genes are
also up-regulated in the invasive cancer dataset. Functionally
related genes not included within Table 5, include the
oxidoreductases SRXN1 and AKR1B10. SRXN1 expression
protects against cigarette smoke-induced oxidative stress, and is
important for redox homeostasis [90,91,92]. Similar to AKR1C1,
AKR1B10 catalyzes NADPH-dependent reduction and
inhibition of 4-HNE and other toxic aldehydes resulting from
peroxidation of membrane lipids [93]. The pentose phosphate
pathway (PPP) provides reducing equivalents for glutathione
reduction/recycling and maintenance of redox status; three genes
associated with the PPP (ALDOC, G6PD, TKTL1), are up-
regulated in CIS lesions. Expression of many of these genes
(AKR1B10, AKR1C1, AKR1C3, G6PD, GPX2, GSTM1,
GSTM3, GSTM4, SRXN1) is regulated by the redox-sensitive
NRF2 transcription factor, and is induced by cigarette smoke
[94,95,96,97]. However, these protective responses may also
promote adaptation to adverse environmental conditions (redox
stressors), and survival with propagation of damaged cells. For
example, SRXN1 may play a role in development of skin
malignancies [92]. Both AKR1C isoforms and AKR1B10
catalyze oxidative activation of xenobiotic proximate carcinogen
PAH trans-dihydrodiols (such as B[a]P, a component of cigarette
smoke), to generate reactive ortho-quinones, and mediate redox
cycling with ROS amplification [98]. Over-expression of
AKR1B10 and AKR1C1 has been reported for many cancer
types [99]. Expression of NRF2-regulated anti-oxidant/
glutathione metabolic gene HMOX1, and NCF1 (the p47phox
subunitofNADPHoxidase, amajor cellular source of ROS)is up-
regulated in CIS lesions, but is also relatively high in precancerous
lesions (Figure 4, Table S2), suggesting that xenobiotic/oxidative
stress may initiate early in the pathway leading to invasive lung
cancer. It has recently been suggested that NADPH oxidase may
stimulate the protective activity of the NRF2-KEAP1 signaling
pathway [100].
Tissue fibrosis. Tissue fibrosis, initiated in response to injury
and facilitated by inflammatory mediators, is characterized by the
excessive accumulation of extracellular matrix components. Genes
typically associated with tissue fibrosis, and up-regulated in the
invasive SCC dataset described in this study, include fibrillar
collagens and other fibrillar matrix components, matrix
metalloproteases, metalloprotease inhibitors, proteoglycans,
chemotactic proteins, transcriptional regulators, and contractile
proteins (Table 6). In addition to those genes identified by IPA,
other genes within the invasive cancer dataset associated with
tissue fibrosis include extracellular proteins MFGE8 [101], and
POSTN, a mediator of collagen fibrillogenesis [102,103][104].
Related genes up-regulated in the SCC dataset include
SAGE of Lung Pre-Cancer
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[105,106], FBLN1 [107], and the small leucine-rich proteoglycan
FMOD, a mediator of collagen fibrillogenesis and matrix assembly
[108]. In addition to structural properties, many of these
components, such as MFAP2, MFGE8, and POSTN have
signaling activities relevant to cancer development
[109,110,111,112,113].
Tissue fibrosis is a component of various cancer types, and
studies suggest that advanced fibrosis contributes to aggressiveness
and resistance to chemotherapy [114,115] [116]. The myofibro-













burn 3.35E-08 COL12A1, COL17A1, COL1A1, COL1A2, COL3A1, COL4A1,
COL5A1, COL6A3
8
Ehlers-Danlos syndrome 5.63E-06 COL1A1, COL1A2, COL3A1, COL5A1 4
Ehlers-Danlos syndrome, type I 2.77E-04 COL1A1, COL5A1 2
psoriatic arthritis 8.43E-05 CD27, IGHG1, IGKC, IL23A, MAP4K1 5
psoriatic arthritis of humans 1.37E-02 IGHG1 1
malignant cutaneous melanoma 5.51E-04 CDK4, CDKN2A 2
dermatological disorder 9.67E-04 5.55E-10 APOE, C1R, C1S, CCL5, CCL20, CD27, CDC25B, CDKN2A, CLDN1,
COL12A1, COL17A1, COL1A1, COL1A2, COL3A1, COL4A1, COL5A1,
COL6A3, CRP, DSG1, FN1, GDF15, GPX2, GRIN2C, IGHG1, IGKC,
IGL@ @, IL23A, JUNB, MAP4K1, ODC1, PERP, PKP1, PSMB4, TP63
34
dermatological disorder of mammalia 3.86E-02 DSG1, IGHG1, IL23A 3
blister 2.49E-03 4.83E-03 COL17A1, DSG1, PLAT 3
blistering of epithelial tissue 6.89E-03 PERP 1
psoriasis 1.30E-02 IGHG1, IL23A, ODC1 3
fibrosis of dermis 1.36E-03 CDK4, COL1A1 2
hereditary angioedema 1.36E-03 C1R, C1S 2
hirsutism 1.37E-02 ODC1 1
metaplasia of squamous epithelium 1.37E-02 TP63 1
skin tumor 2.61E-02 9.26E-03 CDK4, CDKN2A, EFNA1, GPX2, HSP90B1, IL23A, ODC1, RRM2, SPP1 9
Category: Hair and Skin
Development and Function
2
cell spreading of epithelial cell lines 1.01E-04 ANTXR1, CYR61, FN1 3
adhesion of epithelial cell lines 2.16E-04 EPHB3, FN1, POSTN, TIMP3 4
presence of hair follicle 6.89E-03 TP63 1
development of skin 1.18E-04 CLDN1, COL1A1, COL3A1, COL5A1, IRF6 5
tensile strength of skin 2.77E-04 COL5A1, DCN 2
stratification of skin 6.89E-03 TP63 1
proliferation of epidermal cells 8.57E-03 CDK4, EFNA1, IRF6, JUNB 4
thickness of skin tissue 1.37E-02 ODC1 1
mitogenesis of skin cell lines 2.73E-02 IGHG1 1
survival of melanocytes 2.73E-02 EFNA1 1
vascularization of skin 2.73E-02 5.51E-04 MFGE8, ODC1 2
senescence of keratinocytes 1.36E-03 CDK4, CDKN2A 2
arrest in growth of keratinocytes 4.07E-02 TP63 1
differentiation of keratinocytes 4.47E-03 CDKN2A, FN1, IRF6, JUNB 4
growth of melanocytes 4.73E-02 1.89E-03 CDKN2A, EFNA1 2
1IPA Diseases and Disorders.
2IPA Physiological System Development and Function.
3Dermatological Diseases and Conditions: 8.43E-05–3.86E-02; Hair and Skin Development and Function: 6.89E-03–4.73E-02.
4Dermatological Diseases and Conditions: 5.55E-10–9.26E-03; Hair and Skin Development and Function: 1.01E-04–8.57E-03.
5type in bold denotes those genes associated with the corresponding function annotation in the CIS over BE_PC dataset; type in italics denotes those genes associated
with the corresponding function annotation in the SCC over BE_PC dataset; type in both bold and italics denotes those genes associated with the corresponding
function annotation in both the CIS over BE_PC and the SCC over BE_PC datasets. See Table S5 and Table S6 for corresponding tag abundance values.
616 unique genes identified out of 109 IPA eligible mapped IDs within the CIS over BE_PC dataset; 40 unique genes identified out of 153 IPA eligible mapped IDs within
the SCC over BE_PC dataset.
doi:10.1371/journal.pone.0009162.t004
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transformation of resident or bone marrow-derived fibroblasts,
transdifferentiation of epithelial cells to mesenchymal-type cells via
EMT (epithelial-mesenchymal transition), and activation of
resident stellate (astrocyte) cells, is a mediator of tissue fibrosis
[117]. Activation of pancreatic stellate cells mediates the fibrotic
process inherent to pancreatic cancer and contributes to cancer
progression [118,119,120,121]. Activated hepatic stellate cells are
the major mediators of liver fibrosis and contribute to liver cancer
[122,123,124]. The epidermal growth factor receptor regulates
pancreatic fibrosis via stimulation of pancreatic stellate cells [125].
The cellular origins of the tissue fibrosis apparent from analysis of
the invasive lung cancer dataset presented in this study, is not
known. Some genes identified in Table 6 are associated with
hepatic stellate cell activation. Others, including POSTN,
contribute to pancreatic stellate cell activiation [126], and also
mediate EMT [127]. MFGE8 is also a mediator of EMT [111],
and the cytoskeletal intermediate filament protein, VIM (over-
expressed here) is a mesenchymal cell marker, and an indicator of
EMT [128,129,130]. EMT is associated with progression to
invasive cancer [131].
Down-regulated expression changes. We identified 84
SAGE tags to be down-regulated in CIS relative to both BE and
PC (Table S9), and 48 SAGE tags to be down-regulated in
invasive SCC relative to both BE and PC (Table S10), with 31
tags in common (Figure 3B). It is noted that IPA functional
analysis did not identify any down-regulated genes from these
datasets as specifically associated with ciliogenesis, and although
multiple significant functional categories were identified, no
specific biological process within these categories took
prominence (data not shown). This was the case when
analysed separately or as a single dataset of down-regulated
genes, perhaps partially attributed to the relatively small size of
the datasets. However, when based on indirect as well as direct
molecular connections, IPA pathway graphical representation
identified receptor tyrosine kinase ERBB2, as central to a
Figure 6. IPA canonical pathways analysis and toxicity lists analysis of the CIS over BE_PC and the SCC over BE_PC datasets. For
analysis of the CIS over BE_PC dataset, 109 IPA mapped IDs were eligible; for analysis of the SCC over BE_PC dataset, 153 IPA mapped IDs were
eligible. The two sets of data were displayed together using IPA core comparisons, and the 10 most significant functions within Canonical Pathways
and Toxicity Lists are shown above for each dataset. The data in A and C is sorted according to highest significance in CIS over BE_PC, and the data in
B and D is sorted according to highest significance in SCC over BE_PC. The orange line indicates the threshold limit of significance, preset at a p-value
of 0.05.
doi:10.1371/journal.pone.0009162.g006
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addition to associations with multiple developmental processes,
ERBB2 also plays a role in airway repair including
differentiation of ciliated and goblet cells, while inhibiting
squamous metaplasia [132]. In this regard, it is intriguing to
hypothesize that failure to initiate a potential ERBB2 signaling
complex in CIS lesions, may compromise redifferentiation/
restoration of the bronchial epithelium following injury, and
contribute to initiation of in-situ cancer. For further description
of the down-regulated genes identified in Figure S4, see Text
S2.
We performed analysis by Gene Ontology using the GATHER
annotation tool [63] for down-regulated genes in CIS and SCC
relative to BE and PC (Figure S5; Table S8). Genes associated
with defense response were most prominently identified by this
analysis.
Potential biomarkers
Genes expressed at notably different levels among normal and
cancer datasets, have the potential to serve as biomarkers for early
detection. For a listing of potential biomarkers for both CIS and
invasive SCC, based upon a minimal 20-fold up-regulation (and a
minimal average tag abundance of 40 TPM), see Table 7.
Generally, genes associated with epidermal development
(KRTDAP, SPRR2G, SPRR2E) may potentially serve as
biomarkers for CIS, whereas genes associated with immune
response (MHC class I receptor HLA-G, acute-phase response
protein CRP) may potentially serve as biomarkers for invasive
Table 5. Up-regulated genes in CIS and invasive SCC associated with metabolism/detoxification of xenobiotics according to
specific categories within IPA canonical pathways and toxicity lists as indicated.
IPA Canonical & Toxicity CIS/BE_PC
1 SCC/BE_PC
2 Entrez Gene Name Location Type(s)
Aryl Hydrocarbon Receptor
Signaling
CDK4 cyclin-dependent kinase 4 Nucleus kinase
CDKN2A cyclin-dependent kinase inhibitor 2A
(melanoma, p16, inhibits CDK4)
Nucleus transcription
regulator
FASN fatty acid synthase Cytoplasm enzyme
MCM7 MCM7 minichromosome maintenance complex
component 7
Nucleus enzyme
Xenobiotic Metabolism Signaling CHST2 CHST2 carbohydrate (N-acetylglucosamine-6-O)
sulfotransferase 2
Cytoplasm enzyme
CHST3 carbohydrate (chondroitin 6)
sulfotransferase 3
Cytoplasm enzyme
PPP2R1B protein phosphatase 2 (formerly 2A),
regulatory subunit A, beta isoform
Unknown phosphatase
Metabolism of Xenobiotics by
Cytochrome P450; Xenobiotic
Metabolism
AKR1C1 aldo-keto reductase family 1, member C1
(dihydrodiol dehydrogenase 1; 20-alpha
(3-alpha)-hydroxysteroid dehydrogenase)
Cytoplasm enzyme





substrate is a Vitamin (Human)
CYP26A1 cytochrome P450, family 26, subfamily A,
polypeptide 1
Cytoplasm enzyme




GPX2 GPX2 glutathione peroxidase 2 (gastrointestinal) Cytoplasm enzyme
Glutathione Metabolism;







GSTM1 GSTM1 glutathione S-transferase mu 1 Cytoplasm enzyme
GSTM3 GSTM3 glutathione S-transferase mu 3 (brain) Cytoplasm enzyme
GSTM4 glutathione S-transferase mu 4 Cytoplasm enzyme
NRF2-mediated Oxidative Stress
Response
ACTA1 actin, alpha 1, skeletal muscle Cytoplasm other
JUNB jun B proto-oncogene Nucleus transcription
regulator
Oxidative Stress CCL5 chemokine (C-C motif) ligand 5 Extracellular Space cytokine
113 unique genes identified out of 109 IPA eligible mapped IDs. See Table S5 for corresponding tag abundance values.
212 unique genes identified out of 153 IPA eligible mapped IDs. See Table S6 for corresponding tag abundance values.
doi:10.1371/journal.pone.0009162.t005
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expressing cell type(s) for the genes associated with immune
response may warrant further investigation, these genes may
nonetheless accurately reflect the tumor cell microenvironment
and provide diagnostic potential. Multiple literature reports
support the potential of HLA-G and CRP to serve as biomarkers
for invasive cancer of various tissue types including NSCLC
[133,134,135,136,137,138]. Additionally, the data presented in
this study suggests that the neuropeptide NTS, may have potential
as a biomarker for CIS lesions, whereas CST1, a peptidase
inhibitor within the cystatin superfamily, may have potential as a
biomarkers for invasive SCC lesions. Intriguingly, a recent study
describes the potential of CST1 as a urinary marker for colorectal
cancer [139].
Due to rarity of CIS specimens, we were not able to validate up-
regulation of gene expression directly. However, an analysis of
publically available microarray expression data from squamous
lung carcinoma specimens [35], and microarray expression data
from internally profiled bronchial brushings, indicates that genes
associated with epidermal development and showing specific
expression in the CIS SAGE dataset, such as KRTDAP and
SPRR2G, may actually retain up-regulation in a subset of invasive
tumors (Figure S6). Thus, these genes may have potential to serve
as early-stage biomarkers for SCC in a combinatorial manner.
To identify potential biomarkers associated with both preinva-
sive and invasive squamous cell lung cancer, we selected SAGE
tags on the basis of a minimal 20-fold up-regulation in both the
CIS and invasive cancer datasets (relative to BE and PC) (Table 7).
Intriguingly, several of these tags map to immunoglobulin heavy
chain and light chain genes (see above). Other genes identified
here include NTRK2, a member of the neurotrophin tyrosine
kinase receptor family, and GSTM3, a mediator of glutathione/
xenobiotic metabolism (see above). Genetic polymorphisms of
GSTM3 and other members of the GST family of proteins, have










A2M alpha-2-macroglobulin Extracellular Space transporter 17.4 3.2 4.1 0.8
APOE apolipoprotein E Extracellular Space transporter 4.1 3 0.9 0.7
BGN biglycan Extracellular Space other .43 4.3 .5 0.5
CCL5 chemokine (C-C motif) ligand 5 Extracellular Space cytokine 3.1 4.2 1.5 2
CDK4 cyclin-dependent kinase 4 Nucleus kinase 3.9 3 1.7 1.3
CDKN2A cyclin-dependent kinase inhibitor 2A
(melanoma, p16, inhibits CDK4)
Nucleus transcription regulator 11.2 3.5 5.5 1.7
COL1A1 collagen, type I, alpha 1 Extracellular Space other 45 6.4 2 0.3
COL1A2 collagen, type I, alpha 2 Extracellular Space other 160.5 8.2 9 0.5
COL3A1 collagen, type III, alpha 1 Extracellular Space other .284 40.6 .13 1.9
COL4A1 collagen, type IV, alpha 1 Extracellular Space other 285 10.5 46 1.7
COL5A1 collagen, type V, alpha 1 Extracellular Space other .46 6.6 .1 0.1
COL6A3 collagen, type VI, alpha 3 Extracellular Space other .159 4.5 .18 0.5
DCN decorin Extracellular Space other 40 4 16.7 1.7
ECE2
3 endothelin converting enzyme 2 Plasma Membrane peptidase 19.4 4.4 22.4 5.1
FBN1 fibrillin 1 Extracellular Space other 18.5 3.5 7.7 1.5
FN1 fibronectin 1 Plasma Membrane enzyme 38.6 3.9 0.7 0.1
GLIS2 GLIS family zinc finger 2 Nucleus transcription regulator 5.4 10 1.7 3.2
IFI6 interferon, alpha-inducible protein 6 Cytoplasm other 3.2 5.9 2.4 4.5
IFITM1 interferon induced transmembrane
protein 1 (9–27)
Plasma Membrane other 5.1 6.8 1.6 2.2
MMP12 matrix metallopeptidase 12 (macrophage
elastase)
Extracellular Space peptidase 27 4.5 9.5 1.6
MYH7B myosin, heavy chain 7B, cardiac muscle, beta Unknown other .51 4.2 .28 2.3
SPARC secreted protein, acidic, cysteine-rich
(osteonectin)
Extracellular Space other 116 3 33 0.8
SPP1 secreted phosphoprotein 1 Extracellular Space cytokine 17.3 30.2 1.9 3.3
TIMP3
4 TIMP metallopeptidase inhibitor 3 Extracellular Space other 18.5 & 5.5 3.5 & 6.9 3 & 0.9 0.6 & 1.1
1Functions: Organismal Injury and Abnormalities (p value 2.59E-04); Canonical Pathways: Hepatic Fibrosis/Hepatic Stellate Cell Activation; Toxicity Lists: Hepatic Fibrosis.
224 unique genes identified out of 153 IPA eligible mapped IDs.
3Also up-regulated in CIS.
4Two unique tags per gene.
5Ratio of mean TPM for 6 SCC libraries (or 5 CIS libraries) versus mean TPM for 14 BE libraries. Where mean TPM for BE libraries is 0, ratio is cited as ‘‘. mean TPM value’’
for SCC libraries (or CIS libraries).
6Ratio of mean TPM for 6 SCC libraries (or 5 CIS libraries) versus average TPM for 2 PC libraries.
5,6See Table S5 and Table S6 for corresponding tag abundance values.
doi:10.1371/journal.pone.0009162.t006
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Tag






GGCTTCTAAC 0 903 35 31 SPRR2E 95
ACCTCCACTG 0 698 0 10 KRTDAP 91
AATCTCTCAA 16 318 13 0 NTS 95
GTCAAGCCCA 0 165 1 2 SPRR2G 91
CTGCCATTAA 2 89 4 0 OR14J1 47
TTTCCAGCAC 1 75 3 0 C6orf15 95
ACGCCTACTG 0 61 1 2 TKTL1 95
CACAGGCATC 0 58 0 0 nu_sr
5 50
TAACCAAGAG 0 42 0 0 TTR 95
AGGAAGTCTT 1 41 1 0 nu_r
5 48




GATCAGGCCA 0 13 284 7 COL3A1 94
CCACGGGATT 0 10 250 6 No match –
CACCTCCTAT 1 0 239 0 nu_r
5 48
CTGAACTGCA 0 0 133 2 HLA-G 94
GCCGTGAACA 0 0 129 6 SFTPC 94
GAGAGAGACT 0 1 127 2 CRP 95
AGGAAAGGTT 1 0 102 0 Hs.629594 49
GTACACACCC 0 0 78 0 CST1 95
CTAAGAAAGT 2 1 43 0 No match –
CIS and SCC
4
GAAATAAAGC 62 38019 14716 561 IGHG1 94
AAGGGAGCAC 31 5039 3229 32 IGL@ 94
CTCCCCCAAG 33 7043 1969 32 IGHG1 94
CTCCCCCAAA 29 4772 1604 18 IGHG1 94
CAAACTAACC 10 466 516 2 IGHG1 94
GGTTGAAAAA 11 317 348 15 SNAR-E 89
AGAAGACGTT 1 730 240 0 nu_r
5 48
GCGGAGGTGG 2 504 176 3 IGHG1 89
AAATAAAGCA 1 392 174 0 nu_r
5 48
CTGGGTGCCT 0 527 172 3 PSMB4 54
GGAAATAAAG 3 309 134 2 nu_r
5 48
GAAGCCCCAG 0 300 101 0 IGKC 94
AGGGTCCCCG 1 266 97 0 IGKC 94
TGCCGTTTTG 2 192 94 2 GSTM3 92
GAGATAAAGC 0 250 78 3 Hs.682707 48
GAAATAAGGC 2 246 77 0 SLCO1A2 51
TTGAAACTGT 0 67 61 0 MID1 67
GAAATAGAGC 0 190 57 0 nu_r
5 48
TTAAATTAAT 2 51 48 0 NTRK2 94
AGGGGAGCAC 0 45 45 0 LOC100287927 67
1Criteria for potential biomarkers was set at a minimal of 20-fold enhanced expression based on normalized mean tag counts, and a minimal mean abundance level of
40 TPM, in the marker dataset.
2Tags detected at a minimal of 20-fold enhanced expression in CIS relative to BE, PC, and SCC SAGE datasets.
3Tags detected at a minimal of 20-fold enhanced expression in SCC relative to BE, PC, and CIS SAGE datasets.
4Tags detected at a minimal of 20-fold enhanced expression in both CIS and SCC relative to both BE and PC SAGE datasets.
5Tags map to cDNA sequences from the database of Unclustered ESTs.
6Mapping reliability as defined by SAGE Genie.
doi:10.1371/journal.pone.0009162.t007
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PLoS ONE | www.plosone.org 15 February 2010 | Volume 5 | Issue 2 | e9162Figure 7. Correlation between up-regulated gene expression in CIS and SCC relative to BE and PC, with regions of frequent copy-
number gain in CIS specimens. Up-regulated genes (x-axis), plotted according to chromosomal location as indicated, were matched with
segmental copy-number status (y-axis), defined by frequent copy-number gain (blue) and loss (red), from 20 independent CIS specimens. 224 genes
were analyzed, and only those associated with regions gained at a minimal frequency of 0.2 are shown above. Knowledge of losses in addition to
gains serves as a filter to identify those chromosomal regions that are preferentially gained rather than a reflection of general instability. See Table
S12 for raw data pertaining to these analyses.
doi:10.1371/journal.pone.0009162.g007
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expression of NTRK2 has been associated with poor prognosis
in neuroblastoma and other cancer types [143,144,145]. It is noted
that several of the selected tags in Table 7 are currently unmapped
to a gene ID; further experimentation to resolve these mappings
may provide additional genes for biomarker evaluation.
In an effort to evaluate the frequency of over-expression of these
candidate genes in SCC on a broader scale, we again consulted
publically available microarray expression data from squamous
lung carcinoma specimens [35], and microarray expression data
from internally profiled bronchial brushings. Although sporadic, a
trend of up-regulation was observed for COL3A1, SFTPC, CST1,
IGHG1, GSTM3, SLCO1A2, and NTRK2 in squamous tumors
relative to bronchial epithelium, lending support to the potential of
these genes to serve as biomarkers for invasive SCC (Figure S6).
See Table S11 for raw microarray data used for this analysis.
Differential gene expression and genomic copy-number
status in CIS lesions
To investigate whether alterations in gene dosage contributes
mechanistically to the differential gene expression identified here
in early-stage lung cancer, we compared segmental copy number
gain/loss from 20 independent CIS specimens with locus
information for up-regulated and down-regulated genes in CIS/
SCC relative to BE and PC. A subset of up-regulated genes
localized to regions of stable frequent gain (Figure 7), and a subset
of down-regulated genes localized to regions of stable frequent loss
(Figure 8). Most prominently identified corresponding regions of
copy number gain include 1q21–1q42.13 and 3q12.1–3q29, and
loci within chromosomal arms 7q, 8q, 17q, and 20q. It is noted
that the region 1q21 encodes the EDC, a region over-expressed
early in CIS lesions (see above). Most prominently identified
corresponding regions of copy number loss include loci within
chromosomal arms 3p and 6p. This data agrees with previously
published data for lung cancer, particularly amplification at 3q,
7q, 8q, and loss of 3p [146,147,148]. [Notably, a recent study
describes genomic amplification and over-expression of transcrip-
tion factor SOX2 encoded at 3q26.33 in lung squamous cell
carcinoma [149]. Although we detect enhanced expression of
SOX2 in CIS relative to both BE and PC, the tag abundance ratio
falls marginally below the three-fold threshold/cut-off applied in
this study, precluding this gene from the copy-number analysis
presented here.] The data presented here suggests that frequent
chromosomal gain/loss of specific loci, represents a significant
Figure 8. Correlation between down-regulated gene expression in CIS and SCC relative to BE and PC, with regions of frequent
copy-number loss in CIS specimens. Down-regulated genes (x-axis), plotted according to chromosomal location as indicated, were matched with
segmental copy-number status (y-axis), defined by frequent copy-number loss (red) and gain (blue), from 20 independent CIS specimens. 81 genes
were analyzed, and only those associated with regions lost at a minimal frequency of 0.2 are shown above. Knowledge of gains in addition to losses
serves as a filter to identify those chromosomal regions that are preferentially lost rather than a reflection of general instability. See Table S13 for raw
data pertaining to these analyses.
doi:10.1371/journal.pone.0009162.g008
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stages of squamous cell lung cancer. See Table S12 and Table
S13 for raw data describing copy-number status for up-regulated
genes and down-regulated genes, respectively.
Summary
In this study we describe genes differentially regulated in early
stages of squamous NSCLC development by way of SAGE
profiling. Differentially expressed genes found in common between
CIS and precancerous lesions relative to bronchial epithelium, are
presumed to reflect early expression changes during CIS develop-
ment. Those genes differentially expressed in CIS relative to the
precancerous lesions/bronchial epithelium, and in invasive SCC
relative to the precancerous lesions/bronchial epithelium, presum-
ably reflect gene expression changes more instrumental to cancer
initiation, and cancer cell invasion, respectively. In this study, data
was analyzed primarily through the use of Ingenuity Pathway Analysis,
complemented by literature searches pertaining to specific genes.
Here we have described the up-regulation of genes associated with
epidermal development, and the down-regulation of genes
associated with mucociliary development, in both CIS and
precancerous lesions relative to bronchial epithelium. Increased
expression of genes associated with desmosomal cell-cell junctions,
and epidermal barrier formation, would conceivably enhance tissue
integrity, and may reflect a protective response to tissue damage
occurring early in CIS lesions. Although genes associated with
epidermal development are also elevated in SCC, those genes
specifically associated with epidermal barrier formation and
desmosomal structures, show relatively low expression in invasive
SCC, suggesting further tissue architecturalchanges upon transition
to invasive cancer. Our data also suggests that tissue remodeling/
fibrosis is present in early stage CIS lesions, where it may reflect a
cellular response to hypoxia/oxidative stress. Our analysis has
identified up-regulation of genes associated with xenobiotic
metabolism/detoxification in CIS and invasive SCC relative to
bronchial epithelium and precancerous lesions, implying an
enhanced requirement for protection against electrophile and/or
oxidative stress upon the transition from precancer to CIS. Up-
regulated genes specifying tissue fibrosis is a pronounced feature of
the invasive cancer dataset, where it appears in association with
acute phase immune components. Thus, the data presented here
suggests that a fibrotic tissue response is initiated in early stage CIS,
and is further developed in invasive cancer. Considering that many
of these matrix components have signaling activities associated with
regulation of cellular proliferation and migration similar to those
described for EMT, the profibrotic phenotype described here may
represent a defining component of advanced lung SCC. Addition-
ally, by selecting SAGE tags showing extreme up-regulation among
the various datasets, we have identified a small number of genes that
may have potential as biomarkers for early diagnosis. Although
someof these genes have previously been investigatedas biomarkers
for invasive cancer by other researchers, this is the first description
of potential biomarkers for CIS. Lastly, a comparative analysis
between differential gene expression in CIS lesions and invasive
carcinoma with array CGH data from independent CIS specimens,
suggests that copy number alterations plays a significant role in
differential gene expression in CIS lesions.
Supporting Information
Table S1 Most abundant 300 tags in bronchial epithelium,
carcinoma-in-situ, and invasive cancer SAGE datasets.
Found at: doi:10.1371/journal.pone.0009162.s001 (0.39 MB
DOC)
Table S2 Up-regulated gene expression changes in common
between carcinoma-in-situ and precancerous lesions relative to
bronchial epithelium.
Found at: doi:10.1371/journal.pone.0009162.s002 (0.29 MB
DOC)
Table S3 Input for GATHER analysis of gene ontology for
genes showing similar differential expression in CIS and PC.
Found at: doi:10.1371/journal.pone.0009162.s003 (0.39 MB
DOC)
Table S4 Down-regulated gene expression changes in common
between carcinoma-in-situ and precancerous lesions relative to
bronchial epithelium.
Found at: doi:10.1371/journal.pone.0009162.s004 (0.97 MB
DOC)
Table S5 Up-regulated gene expression changes in carcinoma-
in-situ relative to bronchial epithelium and precancerous lesions.
Found at: doi:10.1371/journal.pone.0009162.s005 (0.34 MB
DOC)
Table S6 Up-regulated gene expression changes in invasive
cancer relative to bronchial epithelium and precancerous lesions.
Found at: doi:10.1371/journal.pone.0009162.s006 (0.35 MB
DOC)
Table S7 Summary of real-time RT-PCR data for select
genes within invasive cancer, bronchial epithelium, and lung
parenchyma.
Found at: doi:10.1371/journal.pone.0009162.s007 (0.03 MB
DOC)
Table S8 Input for GATHER analysis of gene ontology for
genes differentially expressed in cancer datasets relative to BE and
PC.
Found at: doi:10.1371/journal.pone.0009162.s008 (0.16 MB
DOC)
Table S9 Down-regulated gene expression changes in carcino-
ma-in-situ relative to bronchial epithelium and precancerous
lesions.
Found at: doi:10.1371/journal.pone.0009162.s009 (0.14 MB
DOC)
Table S10 Down-regulated gene expression changes in invasive
cancer relative to bronchial epithelium and precancerous lesions.
Found at: doi:10.1371/journal.pone.0009162.s010 (0.09 MB
DOC)
Table S11 Microarray expression data for up-regulated genes
with biomarker potential.
Found at: doi:10.1371/journal.pone.0009162.s011 (0.19 MB
DOC)
Table S12 Up-regulated genes in CIS and SCC analyzed for
frequent copy-number gain (and loss) in CIS specimens.
Found at: doi:10.1371/journal.pone.0009162.s012 (0.33 MB
DOC)
Table S13 Down-regulated genes in CIS and SCC analyzed for
frequent copy-number loss (and gain) in CIS specimens.
Found at: doi:10.1371/journal.pone.0009162.s013 (0.14 MB
DOC)
Figure S1 Gene ontology analysis as determined by the
GATHER annotation tool for genes showing similar differential
expression in CIS and PC. Those gene ontology annotations cited
at a minimal depth of five and associated with a positive ln(Bayes
factor) value are shown. The y-axis refers to the total number of
genes per GO annotation. A. Up-regulated genes in CIS and PC
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PLoS ONE | www.plosone.org 18 February 2010 | Volume 5 | Issue 2 | e9162relative to BE (151 genes analyzed). ln(Bayes factor) range 25.15–
0.06 (left to right as indicated). B. Down-regulated genes in CIS
and PC relative to BE (484 genes analyzed). ln(Bayes factor) range
8.04–0.12 (left to right as indicated). A positive Bayes factor
indicates support for the hypothesis that an association of an
annotation with the identified gene cluster is stronger than the
association to other genes in the genome. See Table S3 for exact
listing of gene symbols used as input for GATHER analysis.
Found at: doi:10.1371/journal.pone.0009162.s014 (1.96 MB EPS)
Figure S2 IPA pathway graphical representation for genes
commonly down-regulated in CIS and PC relative to BE. Results
are displayed for 76 gene products characterized by either direct
(solid lines) or indirect (broken lines) connections derived from
analysis of 500 input molecules*. Lines indicate protein-protein
binding interactions, and arrows refer to ‘‘acts on’’ interactions
such as proteolysis, expression, and protein-DNA/RNA interac-
tions. Gene products are positioned according to subcellular
localization. Genes associated with cilia formation (IPA function:
Cellular Assembly and Organization) are highlighted. (See Table
S4 for tag data.) *To comply with the maximum input of 500
mapped IDs for IPA pathway analysis, 8 IDs from the BE over
CIS_PC dataset were excluded from the total of 508 IPA mapped
IDs. These included C10orf79, C13orf30, C16orf46, C1orf110,
C1orf92, C22orf15, C5orf32, and C8orf40, chosen randomly from
within the set of open reading frame genes.
Found at: doi:10.1371/journal.pone.0009162.s015 (6.95 MB EPS)
Figure S3 Gene ontology analysis as determined by the
GATHER annotation tool for genes up-regulated in cancer
datasets relative to BE and PC. Those gene ontology annotations
cited at a minimal depth of five and associated with a positive
ln(Bayes factor) value are shown. The y-axis refers to the total
number of genes per GO annotation. A. Up-regulated genes in
CIS relative to BE and PC (138 genes analyzed). ln(Bayes factor)
range 3.4–0.19 (left to right as indicated). B. Up-regulated genes in
SCC relative to BE and PC (173 genes analyzed). ln(Bayes factor)
range 9.66–0.13 (left to right as indicated). A positive Bayes factor
indicates support for the hypothesis that an association of an
annotation with the identified gene cluster is stronger than the
association to other genes in the genome. See Table S8 for exact
listing of gene symbols used as input for GATHER analysis.
Found at: doi:10.1371/journal.pone.0009162.s016 (3.31 MB EPS)
Figure S4 Genes down-regulated in the CIS and invasive SCC
datasets relative to BE and PC. A. Venn diagram of down-
regulated SAGE tags and corresponding IPA mapped IDs for the
CIS and SCC datasets. (See Table S9 and Table S10 for tag data.)
B. IPA pathway graphical representation for the BE_PC over CIS
dataset (50 unique IDs displayed in green; 26 shared IDs displayed
in gray), and the BE_PC over SCC dataset (15 unique IDs
displayed in red; 26 shared IDs displayed in gray). Gene products
are positioned according to subcellular localization. Both direct
connections (solid lines) and indirect connections (broken lines)
among the individual gene products are shown; lines indicate
protein-protein binding interactions, and arrows refer to ‘‘acts on’’
interactions such as proteolysis, expression, and protein-DNA/
RNA interactions.
Found at: doi:10.1371/journal.pone.0009162.s017 (6.31 MB EPS)
Figure S5 Gene ontology analysis as determined by the
GATHER annotation tool for genes down-regulated in cancer
datasets relative to BE and PC. Those gene ontology annotations
cited at a minimal depth of five and associated with a positive
ln(Bayes factor) value are shown. The y-axis refers to the total
number of genes per GO annotation. A. Down-regulated genes in
CIS relative to BE and PC (74 genes analyzed). ln(Bayes factor)
range 2.23–0.06 (left to right as indicated). B. Down-regulated
genes in SCC relative to BE and PC (39 genes analyzed). ln(Bayes
factor) range 3.5–0.07 (left to right as indicated). A positive Bayes
factor indicates support for the hypothesis that an association of an
annotation with the identified gene cluster is stronger than the
association to other genes in the genome. See Table S8 for exact
listing of gene symbols used as input for GATHER analysis.
Found at: doi:10.1371/journal.pone.0009162.s018 (2.74 MB EPS)
Figure S6 Validation of up-regulated gene expression in invasive
SCC using microarray data. Microarray expression data for 53
squamous lung tumors (SqCC) was downloaded from NCBI Lung
Cancer Dataset, GEO accession number GSE3141 [35], and
microarray expression data for 67 bronchial brushings (Normal)
was internally profiled. Results are shown above for seven genes
up-regulated in the invasive SCC SAGE dataset relative to BE and
PC (COL3A1, CST1, *GSTM3, *IGHG1, *NTRK2, SFTPC,
and *SLCO1A2), and for two genes up-regulated in the CIS
SAGE dataset relative to BE, PC, and invasive SCC (KRTDAP,
SPRR2G). See Table S11 for raw microarray data. *Also up-
regulated in CIS.
Found at: doi:10.1371/journal.pone.0009162.s019 (1.75 MB EPS)
Text S1 Further description of the down-regulated genes
displayed in Figure S2.
Found at: doi:10.1371/journal.pone.0009162.s020 (0.14 MB
DOC)
Text S2 Further description of the down-regulated genes
displayed in Figure S4.
Found at: doi:10.1371/journal.pone.0009162.s021 (0.08 MB
DOC)
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